Varex Imaging (VREX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Aug, 2026Executive summary
Entered into a definitive agreement to be acquired by Teledyne Technologies, a leader in digital imaging and engineered systems.
The transaction is expected to close in early 2027, with both companies operating independently until then.
Communication emphasizes ongoing business continuity and commitment to supplier and customer relationships.
Forward-looking statements highlight anticipated synergies, innovation acceleration, and enhanced global scale.
Voting matters and shareholder proposals
A special meeting of stockholders will be held to vote on the adoption of the Merger Agreement.
Proxy statement and related materials will be filed with the SEC and mailed to stockholders.
Board of directors and corporate governance
Certain directors and executive officers may be deemed participants in the proxy solicitation for the special meeting.
Information on directors, executive officers, and their security holdings is available in prior proxy filings and will be updated in the definitive proxy statement.
Latest events from Varex Imaging
- Shareholders will vote on Varex's merger with Teledyne, with closing expected in early 2027.VREX
Proxy filing - Shareholders will vote on a proposed acquisition by Teledyne Technologies, closing in early 2027.VREX
Proxy filing - Shareholders will vote on a proposed acquisition by Teledyne, expected to close in early 2027.VREX
Proxy filing - Teledyne to acquire Varex Imaging for $18.90 per share in a $1.1B all-cash merger.VREX
Proxy filing - Quarterly revenue up 4% YoY to $211M, net income rebounded, and merger with Teledyne announced.VREX
Q3 2026 - Annual guidance, India ramp, photon counting, and AI drive growth and strategic flexibility.VREX
Jefferies Global Healthcare Conference 2026 - Q2 FY26 revenue rose 1–1.5% to $216M, with non-GAAP EPS at $0.21 and lower leverage from refinancing.VREX
Q2 2026 - Photon counting and industrial growth offset medical softness, with gradual China recovery expected.VREX
Jefferies 2024 Global Healthcare Conference - Q1 revenue up 5% to $200M, margin 35%, strong security orders, and Q2 growth outlook.VREX
Q1 2025